» Articles » PMID: 17575142

C-FLIP: a Key Regulator of Colorectal Cancer Cell Death

Overview
Journal Cancer Res
Specialty Oncology
Date 2007 Jun 19
PMID 17575142
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

c-FLIP is an inhibitor of apoptosis mediated by the death receptors Fas, DR4, and DR5 and is expressed as long (c-FLIP(L)) and short (c-FLIP(S)) splice forms. We found that small interfering RNA (siRNA)-mediated silencing of c-FLIP induced spontaneous apoptosis in a panel of p53 wild-type, mutant, and null colorectal cancer cell lines and that this apoptosis was mediated by caspase-8 and Fas-associated death domain. Further analyses indicated the involvement of DR5 and/or Fas (but not DR4) in regulating apoptosis induced by c-FLIP siRNA. Interestingly, these effects were not dependent on activation of DR5 or Fas by their ligands tumor necrosis factor-related apoptosis-inducing ligand and FasL. Overexpression of c-FLIP(L), but not c-FLIP(S), significantly decreased spontaneous and chemotherapy-induced apoptosis in HCT116 cells. Further analyses with splice form-specific siRNAs indicated that c-FLIP(L) was the more important splice form in regulating apoptosis in HCT116, H630, and LoVo cells, although specific knockdown of c-FLIP(S) induced more apoptosis in the HT29 cell line. Importantly, intratumoral delivery of c-FLIP-targeted siRNA duplexes induced apoptosis and inhibited the growth of HCT116 xenografts in BALB/c severe combined immunodeficient mice. In addition, the growth of c-FLIP(L)-overexpressing colorectal cancer xenografts was more rapid than control xenografts, an effect that was significantly enhanced in the presence of chemotherapy. These results indicate that c-FLIP inhibits spontaneous death ligand-independent, death receptor-mediated apoptosis in colorectal cancer cells and that targeting c-FLIP may have therapeutic potential for the treatment of colorectal cancer.

Citing Articles

Regulation of ER stress-induced apoptotic and inflammatory responses via YAP/TAZ-mediated control of the TRAIL-R2/DR5 signaling pathway.

El Yousfi Y, Fernandez-Farran F, Oliver F, Lopez-Rivas A, Yerbes R Cell Death Discov. 2025; 11(1):42.

PMID: 39904986 PMC: 11794427. DOI: 10.1038/s41420-025-02335-w.


Integrated multiplex analysis of cell death regulators in stage II colorectal cancer suggests patients with 'persister' cell profiles fail to benefit from adjuvant chemotherapy.

Cho S, McDonough E, Graf J, Shia J, Firat C, Urganci N BMJ Oncol. 2025; 3(1):e000362.

PMID: 39886119 PMC: 11347685. DOI: 10.1136/bmjonc-2024-000362.


Role of the YAP/TAZ-TEAD Transcriptional Complex in the Metabolic Control of TRAIL Sensitivity by the Mevalonate Pathway in Cancer Cells.

El Yousfi Y, Mora-Molina R, Lopez-Rivas A, Yerbes R Cells. 2023; 12(19).

PMID: 37830584 PMC: 10571597. DOI: 10.3390/cells12192370.


Targeted splicing therapy: new strategies for colorectal cancer.

Zheng Y, Zhong G, He C, Li M Front Oncol. 2023; 13:1222932.

PMID: 37664052 PMC: 10470845. DOI: 10.3389/fonc.2023.1222932.


Limiting glutamine utilization activates a GCN2/TRAIL-R2/Caspase-8 apoptotic pathway in glutamine-addicted tumor cells.

Yerbes R, Mora-Molina R, Fernandez-Farran F, Hiraldo L, Lopez-Rivas A, Palacios C Cell Death Dis. 2022; 13(10):906.

PMID: 36302756 PMC: 9613879. DOI: 10.1038/s41419-022-05346-y.